MPN10 Tracker
Help patients monitor symptoms with the MPN10 tracker.
What are you looking for?
top
Image
Image
Resources to support you and your patients
JAKAVI® (ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.1
This website is intended for healthcare professionals. Please do not direct patients to this page. Patient resources should be downloaded and forwarded to your patients. Alternatively, you can request hard copies from your local representative.
These resources have been developed by Novartis and are intended for healthcare professionals, to help you get the most out of treating with JAKAVI®.
Image
Real-world treatment evidence – GB
PDF
Real-world insights and findings from a UK physician survey on the use of the BSH guidelines for the diagnosis and management of MF.
Image
Real-world treatment evidence – NI
PDF
Real-world insights and findings from a UK physician survey on the use of the BSH guidelines for the diagnosis and management of MF.
Image
JAKAVI® dosing timeline – GB
PDF
A JAKAVI® treatment timeline that can be used during your patient consultations.
Image
JAKAVI® dosing timeline – NI
PDF
A JAKAVI® treatment timeline that can be used during your patient consultations.
Image
MF risk stratification with IPSS, DIPSS and DIPSS Plus – GB
PDF
A guide to support MF patient risk stratification using the IPSS, DIPSS and DIPSS Plus scoring systems.
Image
MF risk stratification with IPSS, DIPSS and DIPSS Plus – NI
PDF
A guide to support MF patient risk stratification using the IPSS, DIPSS and DIPSS Plus scoring systems.
Image
A guide to JAKAVI® in PV – GB
PDF
A guide to the treatment with JAKAVI® for your patients with PV.
Image
A guide to JAKAVI® in PV – NI
PDF
A guide to the treatment with JAKAVI® for your patients with PV.
Image
HU resistance and intolerance guide
PDF
A guide to support patients with PV, to help identify and manage HU intolerance.
For full product information, please refer to the Summary of Product Characteristics.
These resources have been developed by Novartis and are intended for patients who have been diagnosed with an MPN. These resources will help give patients the confidence and knowledge to discuss their disease and track symptoms effectively. Information provided in these resources should not be considered an alternative to advice from a healthcare professional. Please do not direct patients to this page. Patient resources should be downloaded and forwarded to your patients. Alternatively, you can request hard copies from your local representative.
Image
MPN10 patient brochure
PDF
A brochure specifically designed to help MPN patients record how their symptoms change over time.
Image
MPN10 tracker website
Brochure
An online tool where patients can record and track changes in symptoms over time.
Image
Patient symptom guide
PDF
A guide to help patients identify and better understand symptoms related to their disease.
Image
Understanding MPNs: A guide
PDF
This guide is intended for GB healthcare professionals only.
A guide to support patients with PV who have been initiated on JAKAVI®.
Image
MF essentials guide
PDF
This guide is intended for GB healthcare professionals only.
A guide to support patients with MF who have been initiated on JAKAVI®.
Image
PV essentials guide
PDF
This guide is intended for GB healthcare professionals only.
A guide to support patients with PV who have been initiated on JAKAVI®.
Footnotes & references
BSH, British Society for Haematology; DIPSS, Dynamic International Prostate Symptom Score; GB, Great Britain; HCP, healthcare professional; IPSS, International Prostate Symptom Score; MF, myelofibrosis; MPN, myeloproliferative neoplasm; NI, Northern Ireland; PV, polycythaemia vera.
Reference
JAKAVI® (ruxolitinib) Summary of Product Characteristics.
UK | November 2024 | FA-11208705
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
